You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



Targeting Nonalcoholic Steatohepatitis: An Update on Emerging Treatments

  • Authors: Scott Isaacs, MD, FACP, FACE
  • CME / ABIM MOC Released: 1/23/2023
  • Valid for credit through: 1/23/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for diabetologists and endocrinologists, primary care physicians, and gastroenterologists.

The goal of this activity is for learners to be better able to assimilate data on emerging treatments for nonalcoholic steatohepatitis (NASH) and determine which patients may be candidates for these therapies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanism of investigational treatments for NASH in the context of disease pathology
    • Clinical trials of emerging NASH treatments
  • Have greater competence related to
    • Identifying patients who are at greatest risk for NASH


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Scott Isaacs, MD, FACP, FACE

    Adjunct Assistant Professor of Medicine
    Emory University School of Medicine
    Atlanta, Georgia
    The opinions expressed are those of Dr Isaacs and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Isaacs’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.


    Scott Isaacs, MD, FACP, FACE, has no relevant financial relationships.


  • Kim Storck, PharmD

    Senior Director, Content Development, Medscape, LLC


    Kim Storck, PharmD, has no relevant financial relationships.

  • Laura Jacob, MEd

    Senior Medical Education Director, Medscape, LLC


    Laura Jacob, MEd, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Targeting Nonalcoholic Steatohepatitis: An Update on Emerging Treatments

Authors: Scott Isaacs, MD, FACP, FACEFaculty and Disclosures

CME / ABIM MOC Released: 1/23/2023

Valid for credit through: 1/23/2024, 11:59 PM EST


What is the most common cause of chronic liver disease in the United States? Did you guess "alcohol-related liver disease"? How about "chronic hepatitis C"? At one time, yes, these were the most common causes. But not any longer. The epidemiology of liver disease in the United States has changed.[1] Today, the most common cause of chronic liver disease is nonalcoholic fatty liver disease (NAFLD). And 95% of people with NAFLD do not know they have it.[2]

Medscape recently sat with the world-renowned endocrinologist, educator, and fatty liver disease expert, Scott Isaacs, MD, to explore the alarming rise of NAFLD.

Medscape: What is NAFLD, and how does it impact patients?

Scott Isaacs, MD, FACP, FACE: NAFLD represents a spectrum of fatty liver disease ranging from steatosis to progressive steatosis with inflammation, fibrosis, cirrhosis, and finally, hepatic decompensation (Figure 1).[3] Fueled by the obesity and type 2 diabetes (T2D) epidemics, NAFLD affects approximately 1 in 3 people in the United States.[4] Of them, up to 30% have the more severe form of NAFLD, called nonalcoholic steatohepatitis (NASH).[5] In people with T2D, the prevalence of NASH may exceed 37%.[6] NASH is a risk factor for hepatocellular carcinoma, the leading indication for liver transplant in women, and soon to be the number 1 cause of liver transplant in men.[1,7]

Figure 1. The Spectrum and Progression of NAFLD[4]

But the primary cause of death in people with NAFLD is not liver disease…

Please answer this question to complement your learning experience.

  • Print